secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K
Filed at:   2023-11-03T23:59:59+00:00
Accession:  0001193125-23-270370
Event type: leadership
Sentiment:  neutral
Materiality: 0.80
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioMarin CEO Jean-Jacques Bienaimé retiring; Alexander Hardy appointed new CEO
------------------------------------------------------------------------------

- Jean-Jacques Bienaimé retires as President, CEO and Chairman on Nov 30, 2023; remains on board until 2024 annual meeting.
- Alexander Hardy (ex-Genentech CEO) becomes President and CEO and joins board effective Dec 1, 2023.
- Hardy receives $1,050,000 annual base salary, $900,000 signing bonus, and ~$15.5M in equity grants with multi-year vesting.
- Bienaimé eligible for 2023 bonus at 120% of base salary if he remains director/consultant; consulting pays $146k/mo then $73k/mo.
- Lead independent director Richard A. Meier becomes Board Chair effective Dec 1, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000119312523270370/0001193125-23-270370-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000119312523270370/d578678d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-270370

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer